Management
Board of Directors



Craig R. Smith, M.D. joined the Company as a Director at the Company’s inception in July 1993. Dr. Smith was elected President and Chief Executive Officer in August 1993 and was elected Chairman of the Board in January 1994. Prior to joining the Company, Dr. Smith was Senior Vice President for Business and Market Development at Centocor, Inc., a biotechnology corporation. Before joining Centocor, Dr. Smith served on the Faculty of the Department of Medicine at Johns Hopkins Medical School. Dr. Smith received his M.D. from the State University of New York at Buffalo in 1972 and received training in Internal Medicine at Johns Hopkins Hospital from 1972 to 1975. Dr. Smith serves on the Boards of the Maryland Chapter of the Cystic Fibrosis Foundation, the Greater Baltimore Committee, and the Greater Baltimore High Tech Council. Dr. Smith also serves as Chair for the Advisory Council for the Institute of Basic Biomedical Sciences at Johns Hopkins University.


John P. Brennan joined the Company as Vice President, Operations in January 1994 and became Senior Vice President, Operations in January 1997. From 1980 to 1993, he was Vice President, Technical Operations and Manufacturing for G.D. Searle and Co., where he was responsible for the operation of manufacturing plants in North America, Latin America and Europe and the worldwide pharmaceutical and process technology. Mr. Brennan received his B.S. in Chemistry from the Philadelphia College of Pharmacy and Science in 1968 and attended the Wharton Graduate Management Program in 1976.

Margaret M. Contessa joined Guilford as Vice President of Human Resources in November 2000. In February 2002, Ms. Contessa became Sr. Vice President, Human Resources. Prior to joining Guilford, from March 1998 to January 1999, Ms. Contessa was Vice President, Human Resources of Witco Corporation, a 6,000-person, multibillion-dollar manufacturer of specialty chemicals located in Greenwich, Connecticut. From 1986 through 1998, she was employed by Engelhard Corporation as Director, Human Resources, and prior to that held various human resources positions with Schering Plough and BASF. Ms. Contessa received her B.S. in Management Science at Fairleigh Dickinson University in 1977 and received training at Harvard and Columbia University.

Michael Kelly joined the Company as Vice President, Sales & Marketing in December 2002 and was promoted to Vice President, Commercial Operations in November 2003. Prior to this he served as Vice President, Sales for ViroPharma Inc.. Mr. Kelly is an accomplished sales and marketing executive with over 15 years experience in the industry. During his tenure at ViroPharma he was responsible for developing and implementing a corporate sales plan, which included recruiting and training a 214-person primary care sales force and developing promotional programs which helped to establish the company's co-marketed product, Nasacort®AQ nasal spray, as the fastest growing product in its class. Prior to serving with Viropharma, Mr. Kelly held various positions in sales for TAP Pharmaceuticals.

William F. Spengler joined the Company as Executive Vice President and Chief Financial Officer in July 2004. Prior to joining Guilford, Mr. Spengler served as President, COO and Director of Osteoimplant Technology, Inc. Before joining Osteoimplant Technology, Inc, he served as Vice President of Finance at The Black & Decker Corporation and was responsible for the financial management of its largest products group with $1.4 billion in annual sales. Prior to this, Mr. Spengler served fourteen years at Bristol-Myers Squibb Corporation, where he was responsible for overseeing mergers and acquisitions and the development of joint venture relationships. Mr. Spengler received his MBA degree in accounting from New York University and a BA in economics at Yale University.

Nancy J. Linck, Ph.D., J.D. joined the Company as Vice President, Intellectual Property in November 1998. In February 2004, she was promoted to Chief Compliance Officer. In February 2002, she was promoted to Sr. Vice President, General Counsel & Corporate Secretary. From 1994 to 1998, Dr. Linck was Solicitor for the U.S. Patent and Trademark Office, where she acted as general counsel for the Commissioner of Patents and Trademarks. From 1987 to 1994, Dr. Linck worked as a patent and trademark litigator at the intellectual property law firm of Cushman, Darby & Cushman, first as an Associate from 1987 to 1990, and later as a Partner from 1991 to 1994. Since 1995, Dr. Linck has been engaged as an Adjunct Professor of Law, first at George Washington University School of Law and presently at Georgetown University Law Center. Dr. Linck received her B.S. in Chemistry from the University of California, Berkeley, her M.S. and Ph.D. in Inorganic Chemistry from the University of California, San Diego, and her J.D. from Western New England College School of Law.

William C. Vincek, Ph.D. joined the Company as Vice President, Corporate Quality in August 1997. In August 1999, he became Vice President, Pharmaceutical & Chemical Development. In February 2002, Dr. Vincek was then promoted to Sr. Vice President, Pharmaceutical & Chemical Development. In September 2003, Dr. Vincek was promoted to Sr. Vice President, Development. From November 1993 until Dr. Vincek joined the Company, he was Group Director, CMC & Preclinical Regulatory Affairs and Global Research and Development GMP Quality Assurance at Glaxo Wellcome, Inc. Prior to that time, Dr. Vincek held various positions at SmithKline Beecham Pharmaceuticals and related entities. Dr. Vincek received his Ph.D. in Medicinal Chemistry from the University of Kansas, where he also received an M.S. in Medicinal Chemistry. Dr. Vincek received a B.S. in Chemistry from Colorado State University.

Thomas C. Seoh joined the Company in April 1995, as Vice President, General Counsel and Secretary. In August 1999, he was promoted to Senior Vice President. In February 2002, he became Senior Vice President, Corporate and Commercial Development and Strategic Planning. Mr. Seoh previously held legal management positions with ICN Pharmaceuticals, Inc. group, including Vice President and Associate General Counsel, and with Consolidated Press U.S., Inc., and was associated with the New York and London offices of Lord Day & Lord, Barrett Smith. Mr. Seoh received his J.D. and A.B. from Harvard University.

Denise Battles joined the Company as Director of Quality Assurance in August 1994 and became Senior Director of Product Compliance in August 1997. Ms. Battles was promoted to Vice President of Corporate Quality in August 1999. Prior to joining the Company, Ms. Battles was employed by Pharmaceutical Systems, Incorporated as the Director of Quality Assurance and held various positions with Quality Control and Quality Assurance at Baxter Healthcare Corporation. Ms. Battles received her B.S. in Biology from Fisk University in 1977 and received training at the Lake Forest Graduate School of Management.

Barbara S. Slusher, Ph.D. joined the Company in January 1995 as Principal Scientist and Group Leader in Research and Development. Dr. Slusher was promoted to Senior Vice President, Research in August 2002 after being named Vice President, Biology in February 2000. From April 1992 until Dr. Slusher joined Guilford, she was Senior Research Pharmacologist for Zeneca Pharmaceuticals Inc. Dr. Slusher received her Ph.D. in Pharmacology and Molecular Sciences from the Johns Hopkins School of Medicine in 1991 and her Master's degree in Management from the Johns Hopkins School of Continuing Studies in 1991. Dr. Slusher received her B.S. degree in Chemistry from Dickinson College in 1986.

Asher M. Rubin, Vice President, Deputy General Counsel and Corporate Secretary joined Guilford in October 2000, as Senior Corporate Counsel and Assistant Secretary. In February 2004, he was promoted to Vice President, General Counsel & Secretary. He was promoted to Associate General Counsel and Assistant Secretary in August 2001, to Deputy General Counsel and Assistant Secretary in February 2002, and to Vice President, Deputy General Counsel and Secretary in February 2003. Prior to joining the Company, Mr. Rubin was an associate with the law firm of Miles & Stockbridge P.C., in Baltimore, Maryland from February 1997 through October 2000. Mr. Rubin received his A.B. in Policy Sciences and Public Affairs from Duke University in 1992 and his J.D. from the University of Maryland School of Law in 1995.

Russell Wesdyk joined the Company as Senior Director, Business Development in July 2002 and was promoted to Vice President, Business Development in February 2004. Prior to joining the Company, Mr. Wesdyk was employed at Bristol-Myers Squibb Co., from 1985 - 2002, where he held a variety of senior management positions, most recently as Director, Corporate Development. In this position Mr. Wesdyk managed multiple acquisition/divestiture or licensing deals and was responsible for creating business development strategy for the U.S. primary care market for Bristol-Myers Squibb. Mr. Wesdyk received his B.S in chemistry at Seton Hall University and an M.B.A. at Fairleigh Dickinson University.



Craig R. Smith, M.D.
Chairman of the Board of Directors, and Chief Executive Officer, member of the Science Committee and member of the New Hire Option Committee.

Dr. Smith joined the Company as a Director at the Company’s inception in July 1993. Dr. Smith was elected President and Chief Executive Officer in August 1993 and was elected Chairman of the Board in January 1994. Prior to joining the Company, Dr. Smith was Senior Vice President for Business and Market Development at Centocor, Inc., a biotechnology corporation. Before joining Centocor, Dr. Smith served on the Faculty of the Department of Medicine at Johns Hopkins Medical School. Dr. Smith received his M.D. from the State University of New York at Buffalo in 1972 and received training in Internal Medicine at Johns Hopkins Hospital from 1972 to 1975. Dr. Smith serves on the Boards of the Maryland Chapter of the Cystic Fibrosis Foundation, the Greater Baltimore Committee, and the Greater Baltimore High Tech Council. Dr. Smith also serves as Chair for the Advisory Council for the Institute of Basic Biomedical Sciences at Johns Hopkins University.


George L. Bunting, Jr.
Director and Chairman of the Compensation Committee and member of the Audit Committee.

Mr. Bunting has been a Guilford director since May 1996. Mr. Bunting is president and chief executive officer of Bunting Management Group, a position he has held since July 1991. He formerly served as chairman of the board and chief executive officer of the Noxell Corporation (a Procter and Gamble Company as of November 1989). Mr. Bunting joined Noxell Corporation in 1966 as a product manager. In 1968, he was elected to the board of directors of Noxell. In March 1970, he was elected to the position of executive vice president and served as president and chief executive officer from November 1973 until April 1986, when he became chairman and chief executive officer. Mr. Bunting is a director of Mercantile Bankshares Corporation, Baltimore Equitable Insurance Company and Mercantile Safe Deposit and Trust Company. He served as Chairman of the Board of Trustees of the Johns Hopkins Health System, and Johns Hopkins Hospital from 1994 until 1998 and for Johns Hopkins Medicine from 1996 until 1998. Mr. Bunting continues to serve as a trustee for these institutions as well as Johns Hopkins University.


Joseph R. Chinnici
Director and member of the Audit Committee.

Mr. Chinnici joined the Board of Directors for Guilford in 2002. He currently serves as Senior Vice President, Finance and Chief Financial Officer at CIENA Corporation, a leading provider of intelligent optical networking systems and software, located in Linthicum, Maryland. Before being promoted to this position, he served as Vice President, Finance and Chief Financial Officer from May 1995 to August 1997, and Controller from September 1994 to May 1995. Previously, Mr. Chinnici acted as a financial consultant for Halston Borghese Inc., and held a variety of finance and accounting assignments with Playtex Apparel. Mr. Chinnici holds a B.S. degree in accounting from Villanova University and an M.B.A. from Southern Illinois University. Mr. Chinnici also currently serves on the board of directors for TR Systems.


Barry M. Fox
Director and member of the Compensation Committee.

Mr. Fox is a partner at the law firm of Cleary, Gottlieb, Steen & Hamilton, an international law firm based in New York City. Mr. Fox joined Guilford's Board in September 2002. Mr. Fox joined Cleary, Gottlieb in 1974 and became a partner in 1981. Mr. Fox received a J.D. degree, cum laude, in 1969 from Harvard Law School, where he was editor of the Harvard Law Review from 1967 to 1969. He received an undergraduate degree from Johns Hopkins University in 1965.


Elizabeth M. Greetham
Director and member of the Compensation Committee.

Ms. Greetham has been a Guilford director since November 1995. From 1992 to 1999, Ms. Greetham was portfolio manager of WPG Life Sciences Fund, L.P. and WPG Institutional Life Sciences Fund, L.P., and since 1990 she had been involved in health care investments for institutional, growth and individual high net worth accounts at Weiss, Peck & Greer, L.L.C. From June 1999 until August 2000, Ms. Greetham was Chief Financial Officer of Drug Abuse Sciences, Inc. In August 2000, Ms. Greetham was named Chief Executive Officer of Drug Abuse Sciences, Inc. She is a member of the Board of Directors of Drug Abuse Sciences, Inc.


Skip Klein
Director and member of the Audit Committee and Science Committee.

Mr. Klein has been a Guilford director since August 1998. Mr. Klein is currently Managing Member of Gauss Capital Advisors, LLC, a consulting and investment advisory firm focused on medical technology, and a Venture Partner of MPM Capital, one of the largest venture capital firms devoted exclusively to the life sciences. Mr. Klein has over 15 years of experience as a health care portfolio manager and securities analyst at The Kaufmann Fund and T. Rowe Price Associates, Inc., including conceiving, launching and successfully managing the T. Rowe Price Health Sciences Fund for its first two years. From June, 1999, to September, 2000, Mr. Klein served as Vice President, Strategy for Medical Manager Corporation where he assisted senior executives until the company merged with WebMD Corporation. Mr. Klein earned an MBA from the Stanford Graduate School of Business, and a B.A. in economics, summa cum laude, from Yale University, where he was elected to Phi Beta Kappa. Mr. Klein is also a Director of NPS Pharmaceuticals, Inc.


Ronald Nordmann
Director, Chairman of the Audit Committee and Chairman of the Nominating Committee.

Mr. Nordmann became a Guilford Director in May 2000. Mr. Nordmann is currently Co-President of Global Health Associates, LLC (a consulting firm to life sciences companies). From 1994 until January 2000, Mr. Nordmann was a partner at Deerfield Management, a health care investment management firm where he served as an analyst and portfolio manager of a $1.2 billion health care sector fund. Prior to joining Deerfield Management, Mr. Nordmann was the Managing Director and Senior Health Care Analyst at PaineWebber Incorporated (a broker dealer) for approximately nine years. Mr. Nordmann has over 25 years experience in investment management specializing in the pharmaceutical industry. He received his B.A. in Business and Industrial Management from The Johns Hopkins University in 1963 and his MBA in Finance and Marketing from Fairleigh Dickinson University in 1966. Mr. Nordmann serves on the Boards of Directors of Shire Pharmaceuticals Group plc, Pharmaceutical Resources, Inc. and is a Trustee of The Johns Hopkins University.


Solomon H. Snyder, M.D.
Director, Chairman of the Science Committee, member of Nominating Committee and consultant to Guilford.

Dr. Snyder has been a Guilford director since Guilford's inception in July 1993 and a consultant of ours since August 1993. Dr. Snyder received his M.D. in 1962 from Georgetown Medical School, trained as a research associate with Julius Axelrod at the National Institute of Mental Health and completed his Psychiatry Residency at Johns Hopkins Hospital. He is presently director of the Department of Neuroscience at Johns Hopkins Medical School and Distinguished Service Professor of Neuroscience, Pharmacology and Molecular Sciences, and Psychiatry. Dr. Snyder has received a number of awards including the Albert Lasker Award in Basic Biomedical Research, the Wolf Prize and the Bower Award. He is a member of the U.S. National Academy of Sciences, the Institute of Medicine and the American Academy of Arts and Sciences. Dr. Snyder is a director of Scios.


W. Leigh Thompson, M.D., Ph.D.
Director and member of the Compensation Committee and Science Committee.

Dr. Thompson has been a Guilford director since April 1995. Dr. Thompson joined Eli Lilly in 1982 and was appointed executive vice president for research in 1991 and chief scientific officer in 1993. Dr. Thompson retired from Eli Lilly in December 1994 and is currently an independent consultant (advising clients in the pharmaceutical industry). Dr. Thompson was a Professor of Medicine at Case Western Reserve University and President of the Society of Critical Care Medicine. Dr. Thompson is a Director of DepoMed, Inc., Inspire Pharmaceuticals, Inc., La Jolla Pharmaceutical Co., Medarex, Inc., Orphan Medical, Inc., Bioanalytical Systems, Inc., Conjuchem, Inc., Diabetogen and Sontra.


David C. U’Prichard, Ph.D.
Director and member of the Science Committee.

Dr. U’Prichard joined the Board of Directors in December 2003. He is currently President of Druid Consulting LLC, a specialized pharmaceutical and biotechnology-consulting firm, which provides customized services to life sciences clients in the United States and Europe. Dr. U’Prichard is also a Venture Partner and member of the health care team of Apax Partners Ltd., a global private equity provider. Previously, he was Chief Executive Officer of 3-Dimensional Pharmaceuticals (3DP) from 1999 to 2003. In addition, Dr. U’Prichard has held a variety of positions within the pharmaceutical and biotechnology industries, including, acting as President and Chairman of Research and Development for SmithKline Beecham Pharmaceuticals; Executive Vice President and International Research Director, and a Member of the Board of Zeneca Pharmaceuticals; General Manager Research Department, ICI Pharmaceuticals, and Vice President Biomedical Research, ICI Pharmaceuticals, and Senior Vice President and Scientific Director for Nova Pharmaceutical Corporation. He is currently a member of the board of directors of the Life Sciences Research Foundation in Baltimore, Maryland, and is a member of the board of directors of Lynx Therapeutics, ExSAR Corporation and Predict, Inc. Dr. U’Prichard is also Chairman of the board of directors for the Pennsylvania Biotechnology Association. From 1992 to 1997 Dr. U’Prichard was a member of the board of the Biotechnology Industry Organization (BIO), an international association of more than 1,000 biotechnology companies, academic institutions, biotechnology research centers and related organizations representing 33 nations.



This page was last updated on Monday, June 28, 2004

Copyright© 2002 Guilford Pharmaceuticals Inc.
Legal Information